Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 120 biologics in R&D and 40 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular and Metabolic diseases

Phase 1

Phase 1

  • MEDI5884 cardiovascular
  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes/obesity
  • MEDI6012 cardiovascular

Phase 3

Phase 3

Oncology

Phase 1

Phase 1

  • Imfinzi (durvalumab) + AZD1775 solid tumours
  • Imfinzi (durvalumab) + Iressa non-small cell lung cancer
  • Imfinzi (durvalumab) + MEDI0562 solid tumours
  • Imfinzi (durvalumab) + MEDI9197 solid tumours
  • Imfinzi (durvalumab) + MEDI9447 solid tumours
  • Imfinzi (durvalumab) + dabrafenib + trametinib melanoma
  • Imfinzi (durvalumab) + monalizumab solid tumours
  • Imfinzi (durvalumab) + selumetinib solid tumours
  • Imfinzi (durvalumab) + tremelimumab solid tumours
  • Imfinzi (durvalumab) or Imfinzi (durvalumab) + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • Imfinzi (durvalumab) solid tumours
  • Imfinzi (durvalumab) + AZD5069 pancreatic ductal adenocarcinoma
  • Imfinzi (durvalumab) + AZD5069 Imfinzi (durvalumab) + AZD9150 head and neck squamous cell carcinoma
  • Imfinzi (durvalumab) + MEDI0680 solid tumours
  • Imfinzi (durvalumab) + tremelimumab hepatocellular carcinoma (liver cancer)
  • Imfinzi (durvalumab) + tremelimumab gastric cancer
  • MEDI-573 metastatic breast cancer

Phase 3

Phase 3

  • Imfinzi (durvalumab) + tremelimumab ARCTIC 3rd-line non-small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab CASPIAN 1st-line small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi (durvalumab) + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi (durvalumab) + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi (durvalumab) + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab + chemotherapy POSEIDON 1st-line non-small cell lung cancer
  • moxetumomab pasudotox PLAIT hairy cell leukaemia

Respiratory

Phase 1

Phase 1

  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

Other

Phase 1

Phase 1

  • MEDI1814 Alzheimer’s disease
  • MEDI7352 osteoarthritis pain
  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

Phase 3

Phase 3

Terminations


LCM Projects - Oncology


AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.